$ALAB

Dyckerhoff Stefan A sold $4.0M of ALAB (indirect holdings)

Dyckerhoff Stefan A sold 8,994 indirectly-held shares of Astera Labs, Inc. (ALAB) at $450.00 ($4.05M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Dyckerhoff Stefan A
Published Jul 2, 2026, 11:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALAB
Neutral
high confidence
Mentioned
$ALAB
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALABNeutralLow
01

Why it matters

The newest fact is the director’s $4.05M open-market sale executed July 1 under a 10b5-1 plan; the filing itself is the actionable datapoint for positioning/flow monitoring.

02

Market read

Traders may monitor insider activity for sentiment/flow, but this specific disclosure lacks new fundamentals and is likely low impact.

03

What to watch

The sale is explicitly under a pre-arranged 10b5-1 plan and is indirect holdings; without additional context (e.g., net selling trend, other filings), the signal is weak.

Relevance 5/10Novelty 5/10Timing: Filed July 2; sale executed July 1 (after-hours/next-session context).

Background

The article is an SEC Form 4 insider transaction disclosure for Astera Labs, Inc. (ALAB).

Company-level read

Ticker impact

$ALABNeutralHigh confidence
Context

Astera Labs director Dyckerhoff Stefan A filed a Form 4 selling 8,994 shares at $450 on a 10b5-1 plan, totaling $4.05M.

Expected impact

Likely limited near-term impact; any effect should be small and transient versus broader company catalysts.

Evidence & confidence

The filing is an insider sale under a pre-arranged 10b5-1 plan, with no accompanying new operational, financial, or regulatory information in the text.

Market effects

No sector read-through is provided; the disclosure is company-specific and does not mention peers or industry developments.

None indicated; the event is an SEC Form 4 insider transaction.

None indicated; no cross-border deal, regulation, or supply-chain event is described.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as reduced conviction, potentially adding mild overhang.

Key entities

  • Astera Labs, Inc.

    Subject of the Form 4 insider transaction; director Dyckerhoff Stefan A sold shares under a 10b5-1 plan.

  • Dyckerhoff Stefan A

    Director who executed the sale; reported as an open-market transaction with indirect holdings.

Related articles

$ALABMed

Astera Labs Beat And Guided Higher, Then Fell Because The Rally Came First

Astera Labs (ALAB) reported record fiscal Q2 2026 results, with revenue of $392.4M up 104% year over year, and issued fiscal Q3 2026 guidance of $540M to $560M, above expectations. The stock later fell about 12% after four prior up sessions. The article attributes the shift to product mix, with PCIe 6 and Scorpio switch family ramping, and a non-GAAP gross margin guide down to about 72% from 74%.

$ALABHighAI 9/10

Astera Labs Q2 Earnings Call Highlights

Astera Labs (NASDAQ:ALAB) said on its Q2 earnings call that a lead Scorpio X customer is expected to ramp to high-volume production in Q3, with Scorpio X revenue expected to exceed Scorpio P-Series in that period. Management forecast Q3 revenue of $540 million to $560 million, non-GAAP gross margin about 72%, and non-GAAP EPS of $1.16 to $1.21.

$ALABHighAI 9/10

Astera Labs Q2 Earnings Beat on PCIe 6 and Scorpio Strength

Astera Labs reported Q2 2026 non-GAAP EPS of 80 cents, up 81.8% YoY and 15.94% above the Zacks Consensus. Revenue rose 104.4% YoY to $392.4 million, beating estimates. Management cited PCIe 6 and Scorpio X-Series strength. Q3 guidance calls for $540-$560 million revenue and $1.16-$1.21 non-GAAP EPS.

$ALABMedAI 8/10

ALAB Q2 Earnings Call Puts Scorpio Ramp Ahead of Schedule

Astera Labs (ALAB) said its Q2 2026 results reflected an earlier-than-expected production ramp for Scorpio fabric switches and a planned Q3 revenue step-up. Q3 revenue guidance is $540-$560 million, midpoint 40% sequential growth. Q2 revenue rose to $392.4M, non-GAAP EPS 80 cents, and margins improved.